Atossa Therapeutics, Inc. said CVR holders are entitled to 25% of net proceeds from monetizing its first priority review voucher, capped at $50 million. Third-quarter operating expenses were $5.9 million, down from $9.3 million.
ATOS · Atossa Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 60%
- Last earnings
- Mar 25, 2025
- Latest filing
- 10-Q · Nov 10
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.
Atossa Therapeutics declared one stapled contingent value right per common share, payable from 25% of net proceeds of the first FDA priority review voucher awarded by December 31, 2036, up to $50 million. No voucher has been awarded.
Atossa Therapeutics approved a plan to issue one contingent value right per common share, entitling holders to 25% of net proceeds from monetizing its first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATOS
this stock
Atossa Therapeutics, Inc.
|
$15.92M | — | -95.6% | — | 5.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 24
Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATOS | -18.6% | -38.7% | -67.1% | -26.5% | -82.0% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -10.1% | -29.4% | -57.9% | -17.8% | -83.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.